Charles Schwab Investment Management Inc Sage Therapeutics, Inc. Transaction History

Charles Schwab Investment Management Inc

  • $515 Billion
  • Q3 2024

A detailed history of Charles Schwab Investment Management Inc transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 452,193 shares of SAGE stock, worth $2.59 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
452,193
Previous 408,576 10.68%
Holding current value
$2.59 Million
Previous $4.44 Million 26.53%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024
BUY
$7.02 - $13.08 $306,191 - $570,510
43,617 Added 10.68%
452,193 $3.26 Million
Q2 2024

Aug 12, 2024
BUY
$10.58 - $17.9 $226,803 - $383,722
21,437 Added 5.54%
408,576 $4.44 Million
Q1 2024

May 08, 2024
SELL
$18.62 - $26.95 $498,382 - $721,343
-26,766 Reduced 6.47%
387,139 $7.25 Million
Q4 2023

Feb 06, 2024
BUY
$17.1 - $22.26 $84,097 - $109,474
4,918 Added 1.2%
413,905 $8.97 Million
Q3 2023

Nov 08, 2023
BUY
$16.75 - $48.98 $298,468 - $872,774
17,819 Added 4.56%
408,987 $8.42 Million
Q2 2023

Aug 09, 2023
BUY
$40.65 - $59.54 $233,778 - $342,414
5,751 Added 1.49%
391,168 $18.4 Million
Q1 2023

May 11, 2023
SELL
$37.27 - $46.57 $5,925 - $7,404
-159 Reduced 0.04%
385,417 $16.2 Million
Q4 2022

Feb 13, 2023
BUY
$32.2 - $43.61 $262,784 - $355,901
8,161 Added 2.16%
385,576 $14.7 Million
Q3 2022

Nov 14, 2022
BUY
$32.28 - $43.27 $250,654 - $335,991
7,765 Added 2.1%
377,415 $14.8 Million
Q2 2022

Aug 15, 2022
BUY
$27.52 - $37.99 $2.8 Million - $3.86 Million
101,705 Added 37.96%
369,650 $11.9 Million
Q1 2022

May 13, 2022
BUY
$30.71 - $45.71 $273,656 - $407,321
8,911 Added 3.44%
267,945 $8.87 Million
Q4 2021

Feb 11, 2022
BUY
$37.06 - $47.11 $114,923 - $146,088
3,101 Added 1.21%
259,034 $11 Million
Q3 2021

Nov 16, 2021
SELL
$40.26 - $57.37 $701,409 - $999,500
-17,422 Reduced 6.37%
255,933 $11.3 Million
Q2 2021

Aug 16, 2021
BUY
$54.88 - $79.29 $399,691 - $577,469
7,283 Added 2.74%
273,355 $15.5 Million
Q1 2021

May 17, 2021
BUY
$70.65 - $96.76 $474,979 - $650,517
6,723 Added 2.59%
266,072 $19.9 Million
Q4 2020

Feb 16, 2021
BUY
$58.41 - $89.06 $202,098 - $308,147
3,460 Added 1.35%
259,349 $22.4 Million
Q3 2020

Nov 13, 2020
BUY
$41.13 - $62.45 $122,279 - $185,663
2,973 Added 1.18%
255,889 $15.6 Million
Q2 2020

Aug 14, 2020
BUY
$25.95 - $43.15 $181,182 - $301,273
6,982 Added 2.84%
252,916 $10.5 Million
Q1 2020

May 15, 2020
BUY
$26.15 - $77.24 $120,394 - $355,612
4,604 Added 1.91%
245,934 $7.06 Million
Q4 2019

Feb 07, 2020
BUY
$60.18 - $154.77 $242,284 - $623,104
4,026 Added 1.7%
241,330 $17.4 Million
Q3 2019

Nov 08, 2019
BUY
$140.29 - $189.96 $1.72 Million - $2.33 Million
12,285 Added 5.46%
237,304 $33.3 Million
Q2 2019

Aug 09, 2019
BUY
$157.85 - $183.09 $1.92 Million - $2.22 Million
12,134 Added 5.7%
225,019 $41.2 Million
Q1 2019

May 14, 2019
BUY
$89.33 - $163.65 $2.35 Million - $4.3 Million
26,278 Added 14.08%
212,885 $33.9 Million
Q4 2018

Feb 14, 2019
BUY
$81.94 - $139.71 $742,048 - $1.27 Million
9,056 Added 5.1%
186,607 $17.9 Million
Q3 2018

Nov 13, 2018
BUY
$138.11 - $169.04 $834,460 - $1.02 Million
6,042 Added 3.52%
177,551 $25.1 Million
Q2 2018

Aug 08, 2018
SELL
$140.36 - $175.76 $8.76 Million - $11 Million
-62,436 Reduced 26.69%
171,509 $26.8 Million
Q1 2018

May 07, 2018
BUY
$152.15 - $192.33 $6.8 Million - $8.6 Million
44,715 Added 23.63%
233,945 $37.7 Million
Q4 2017

Jan 17, 2018
BUY
$60.72 - $167.34 $2.32 Million - $6.39 Million
38,204 Added 25.3%
189,230 $31.2 Million
Q3 2017

Nov 13, 2017
BUY
$61.4 - $88.52 $9.27 Million - $13.4 Million
151,026
151,026 $9.41 Million

Others Institutions Holding SAGE

# of Institutions
218
Shares Held
46.4M
Call Options Held
847K
Put Options Held
188K
View Full List

About Sage Therapeutics, Inc.

SAGE Quotes by TradingView
  • Ticker SAGE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,422,300
  • Market Cap $340M
  • Description
  • Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...
More about SAGE
Track This Portfolio

Track Charles Schwab Investment Management Inc Portfolio

Follow Charles Schwab Investment Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email